[Therapy of advanced XXXX ].

@entity1 @entity263 @entity5 @entity342 @entity1486
@entity263 is a @entity5 . There are about 70 bis 75% responders after hormone therapy among previously untreated @entity1 in EORTC trials. Therefore 25 to 30% of the @entity5 are resistant to @entity342 . Surgical and hormonal castration show similar results. After progression under hormone therapy response can be reached with antiandrogenic therapy in 30 to 38%. All this leads to the conclusion that it is necessary to base treatment on @entity5 adaptation and selection. Cell clones insensitive to @entity342 therefore need cytostatic chemotherapy. It is not yet proofed whether polychemotherapy really shows better results than monotherapy does. Following the thesis of a @entity5 , therapy of @entity263 must be based on hormone therapy and cytostatic chemotherapy. @entity1486 is a marker for an early recognition of progression.
